keyword
MENU ▼
Read by QxMD icon Read
search

antipsychotic switching

keyword
https://www.readbyqxmd.com/read/29618351/hospitalization-outcomes-in-patients-with-schizophrenia-after-switching-to-lurasidone-or-quetiapine-a-us-claims-database-analysis
#1
John W Newcomer, Daisy Ng-Mak, Krithika Rajagopalan, Antony Loebel
BACKGROUND: This study compared hospital admission rates among adult patients with schizophrenia who switched to antipsychotic monotherapy with lurasidone or quetiapine. METHODS: This retrospective cohort study used U.S.-based Truven Health MarketScan® Medicaid Multi-State Database (April 2010 through December 2012) and MarketScan® Commercial Claims and Encounters Database (April 2010 through October 2013). Continuous enrollment for 6-months before and after medication initiation was required...
April 4, 2018: BMC Health Services Research
https://www.readbyqxmd.com/read/29607408/therapeutic-effects-of-prolonged-cannabidiol-treatment-on-psychological-symptoms-and-cognitive-function-in-regular-cannabis-users-a-pragmatic-open-label-clinical-trial
#2
Nadia Solowij, Samantha J Broyd, Camilla Beale, Julie-Anne Prick, Lisa-Marie Greenwood, Hendrika van Hell, Chao Suo, Peter Galettis, Nagesh Pai, Shanlin Fu, Rodney J Croft, Jennifer H Martin, Murat Yücel
Introduction: Chronic cannabis use has been associated with impaired cognition and elevated psychological symptoms, particularly psychotic-like experiences. While Δ9 -tetrahydrocannabinol (THC) is thought to be primarily responsible for these deleterious effects, cannabidiol (CBD) is purported to have antipsychotic properties and to ameliorate cognitive, symptomatic, and brain harms in cannabis users. However, this has never been tested in a prolonged administration trial in otherwise healthy cannabis users...
2018: Cannabis and Cannabinoid Research
https://www.readbyqxmd.com/read/29606876/factors-related-to-improvement-of-symptoms-function-and-caregiver-burden-in-chinese-patients-with-schizophrenia-after-switching-to-paliperidone-palmitate-once-monthly-from-oral-antipsychotics
#3
Nan Li, Yu Feng, Huafei Lu, Shang Li Cai, Jianmin Zhuo, Tianmei Si, Lili Zhang
Background: Paliperidone palmitate once-monthly (PP1M) demonstrated symptomatic and functional remission in patients with schizophrenia. This post hoc analysis aimed to identify factors associated with improved clinical outcomes in patients switching to PP1M (75-150 mg eq.). Methods: The improved patient outcomes were observed as Positive and Negative Symptom Scale (PANSS, symptoms) score <70:66.7% (407/610), Personal and Social Performance (PSP, function) score >70:34...
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29602172/no-differences-in-olanzapine-and-risperidone-related-weight-gain-between-women-and-men-a-meta-analysis-of-short-and-middle-term-treatment
#4
G Schoretsanitis, M Drukker, J Van Os, K R J Schruers, M Bak
OBJECTIVE: A plethora of data deriving from single studies as well as meta-analyses demonstrates that weight gain is associated with the exposure to the majority of antipsychotics (AP). However, potential sex differences have widely evaded the attention of AP treatment trials. It is hypothesised that female patients gain more weight compared with male patients due to their enhanced susceptibility to adverse drug reactions. METHOD: A meta-analysis was conducted using clinical trials of AP that reported weight change separately for female and male patients...
March 30, 2018: Acta Psychiatrica Scandinavica
https://www.readbyqxmd.com/read/29582518/long-term-safety-and-effectiveness-of-brexpiprazole-in-japanese-patients-with-schizophrenia-a-52-week-open-label-study
#5
Jun Ishigooka, Shuichi Iwashita, Yoshihiro Tadori
AIMS: This study assessed the long-term safety, tolerability and maintenance of the therapeutic effect of brexpiprazole in Japanese patients with schizophrenia. METHODS: This 52-week, open-label, flexible-dose (1-4 mg/day) study included patients with schizophrenia who continued treatment from a short-term randomized placebo-controlled fixed-dose (1, 2, or 4 mg/day) trial and de novo patients who switched from other antipsychotics. RESULTS: A total of 282 patients (184 de novo and 98 rolled over from short-term trial) entered the 52-week treatment with brexpiprazole, and 150 (53...
March 26, 2018: Psychiatry and Clinical Neurosciences
https://www.readbyqxmd.com/read/29570965/can-aripiprazole-worsen-psychosis-in-schizophrenia-a-meta-analysis-of-double-blind-randomized-controlled-trials
#6
Hiroyoshi Takeuchi, Ali Fathi, Sadhana Thiyanavadivel, Ofer Agid, Gary Remington
BACKGROUND: Numerous case reports have reported psychotic worsening when switching to or adding aripiprazole in patients with schizophrenia. The risk of psychotic worsening related to aripiprazole was evaluated through a systematic review and meta-analysis. DATA SOURCES: MEDLINE, Embase, and Cochrane Central Register of Controlled Trials were systematically searched using the following keywords: (schizophr* or schizoaff*) AND aripiprazole, with a limitation of randomized controlled trial and English language (last search: September 9, 2016) by the authors in an independent fashion...
March 6, 2018: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/29568276/effects-of-continuing-oral-risperidone-vs-switching-from-risperidone-to-risperidone-long-acting-injection-on-cognitive-function-in-stable-schizophrenia-patients-a-pilot-study
#7
Hikaru Hori, Asuka Katsuki, Kiyokazu Atake, Reiji Yoshimura
Objectives: Risperidone is the first new generation antipsychotic drug to become available as a long-acting injection (LAI). The purpose of this study was to evaluate the effects of switching from oral risperidone to risperidone LAI (RLAI) on cognitive function in stable schizophrenia patients compared with the effects of continuing oral risperidone. Methods: Sixteen stable patients who had received risperidone monotherapy for at least 3 months were enrolled (the RLAI group)...
2018: Frontiers in Psychiatry
https://www.readbyqxmd.com/read/29563800/efficacy-tolerability-and-safety-of-oral-paliperidone-extended-release-in-the-treatment-of-schizophrenia-a-24-week-open-label-prospective-switch-study-in-different-settings-in-taiwan
#8
Ching-Yen Chen, Tze-Chun Tang, Tzu-Ting Chen, Ya Mei Bai, Huei-Huang Tsai, Hou-Liang Chen, Chun-Jen Huang, Chih-Ken Chen, Chun-Chih Chen, Mei-Chun Hsiao, Chia-Yih Liu, Hong-Shiow Yeh, Nan-Ying Chiu, Cheng-Chen Hsiao, Cheng-Sheng Chen, Tung-Ping Su
Purpose: Paliperidone extended release (ER) is an oral psychotropic treatment formulated to release paliperidone at a controlled, gradually ascending rate. We evaluated the efficacy and safety of switching to paliperidone ER in Taiwanese patients with schizophrenia who were unresponsive or intolerant to previous antipsychotic therapy. Patients and methods: This was a 24-week, open-label, single-arm, multicenter, Phase IV trial. Based on consulting psychiatrists' judgment, patients were deemed eligible for the switch to paliperidone ER; the switch was achieved by cross-tapering, using a recommended starting dose of 6 mg...
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29559781/novel-treatment-options-in-depression-and-psychosis
#9
REVIEW
Eva Ceskova, Petr Silhan
In spite of tremendous development in central nervous system research, current treatment is suboptimal, especially in severe mental disorders. In medicine, there are two main methods of improving the health care provided: seeking new treatment procedures and perfecting (optimizing) the existing ones. Optimization of treatment includes not only practical tools such as therapeutic drug monitoring but also implementation of general trends in the clinical practice. New pharmacological options include new more sophisticated forms of monoaminergic drugs, old drugs rediscovered on the base of a better understanding of pathophysiology of mental illnesses, and drugs aimed at new treatment targets...
2018: Neuropsychiatric Disease and Treatment
https://www.readbyqxmd.com/read/29534245/hyper-and-hypomentalizing-in-patients-with-first-episode-schizophrenia-fmri-and-behavioral-studies
#10
Vibeke Bliksted, Chris Frith, Poul Videbech, Birgitte Fagerlund, Charlotte Emborg, Arndis Simonsen, Andreas Roepstorff, Daniel Campbell-Meiklejohn
Background: Historically, research investigating neural correlates of mentalizing deficits in schizophrenia has focused on patients who have been ill for several years with lengthy exposure to medication. Little is known about the neural and behavioral presentations of theory-of-mind deficits in schizophrenia, shortly after the first episode of psychosis. Methods: We investigated social cognition in 17 recently diagnosed first-episode schizophrenia (FES) patients with little or no exposure to antipsychotic medication and 1:1 matched healthy controls...
March 9, 2018: Schizophrenia Bulletin
https://www.readbyqxmd.com/read/29525354/clinical-and-psychopathological-features-associated-with-treatment-emergent-mania-in-bipolar-ii-depressed-outpatients-exposed-to-antidepressants
#11
Michele Fornaro, Annalisa Anastasia, Francesco Monaco, Stefano Novello, Andrea Fusco, Felice Iasevoli, Domenico De Berardis, Nicola Veronese, Marco Solmi, Andrea de Bartolomeis
BACKGROUND: Treatment-emergent affective switch (TEAS), including treatment-emergent mania (TEM), carry significant burden in the clinical management of bipolar depression, whereas the use of antidepressants raises both efficacy, safety and tolerability concerns. The present study assesses the prevalence and clinical correlates of TEM in selected sample of Bipolar Disorder (BD) Type-II (BD-II) acute depression outpatients. METHODS: Post-hoc analysis of the clinical and psychopathological features associated with TEM among 91 BD-II depressed outpatients exposed to antidepressants...
March 1, 2018: Journal of Affective Disorders
https://www.readbyqxmd.com/read/29497196/oculogyric-crisis-with-atypical-antipsychotics-a-case-series
#12
Naresh Nebhinani, Navratan Suthar
Oculogyric crisis (OGC) is an acute dystonic reaction, commonly seen with the administration of typical antipsychotics, and rarely reported with atypical antipsychotics. Here, we report five cases of oculogyric crisis, developed after administration of atypical antipsychotics. The first case developed OGC on quetiapine 800 mg/day and the second case on olanzapine 20 mg/day. Both the patients did not improve on adding anticholinergic agents and finally stabilized by switching to clozapine. The third case developed OGC on amisulpride 400 mg and lurasidone 40 mg/day and improved by reducing amisulpride dose to 200 mg and stopping lurasidone...
October 2017: Indian Journal of Psychiatry
https://www.readbyqxmd.com/read/29465467/outcome-and-predictors-of-remission-in-bipolar-i-patients-experiencing-manic-episode-and-treated-with-oral-antipsychotics-and-or-mood-stabilizers-a-prospective-observational-study-in-italy
#13
Giulio Perugi, Giulia Vannucchi, Margherita Barbuti, Giuseppe Maccariello, Andrea De Bartolomeis, Andrea Fagiolini, Giuseppe Maina
This observational study aimed to identify internal (clinical-demographic, temperamental characteristics) and external (childhood trauma, psychosocial characteristics) factors potentially predicting remission at 12 weeks in bipolar-I patients experiencing manic episode and requiring to start or switch treatment with oral antipsychotics and/or mood stabilizers. The following scales were administered: the Young Mania Rating Scale (YMRS), the Montgomery-Asberg Depression Rating Scale (MADRS), the Functioning Assessment Short Test (FAST), and the Clinical Global Impression for Bipolar Disorders (CGI-BP)...
February 20, 2018: International Clinical Psychopharmacology
https://www.readbyqxmd.com/read/29427512/the-use-of-brexpiprazole-amongst-individuals-with-insufficient-outcomes-with-aripiprazole-or-bupropion-a-case-series
#14
Traci Aladeen, Erica Westphal, Yena Lee, Carola Rong, Michelle Rainka, Horacio Capote, Roger S McIntyre
PURPOSE: We sought to characterize the clinical experience of outpatients treated with brexpiprazole after achieving suboptimal outcomes with aripiprazole or bupropion as determined by the treating psychiatric provider. DESIGN AND METHODS: Case series; inefficacy, intolerability, or other unsatisfactory outcome to previous trial with aripiprazole or bupropion. FINDINGS: The majority of individuals in our sample exhibited tolerability of brexpiprazole...
February 10, 2018: Perspectives in Psychiatric Care
https://www.readbyqxmd.com/read/29427000/tardive-dyskinesia-associated-with-atypical-antipsychotics-prevalence-mechanisms-and-management-strategies
#15
REVIEW
Katharina Stegmayer, Sebastian Walther, Peter van Harten
All antipsychotics, including the atypical antipsychotics (AAPs), may cause tardive dyskinesia (TD), a potentially irreversible movement disorder, the pathophysiology of which is currently unknown. The prevention and treatment of TD remain major challenges for clinicians. We conducted a PubMed search to review the prevalence and etiology of and management strategies for TD associated with AAPs. TD prevalence rates varied substantially between studies, with an estimated prevalence of around 20% in patients using AAPs...
February 9, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29423659/venous-thromboembolism-during-treatment-with-antipsychotics-a-review-of-current-evidence
#16
REVIEW
Anna K Jönsson, Johan Schill, Hans Olsson, Olav Spigset, Staffan Hägg
This article summarises the current evidence on the risk of venous thromboembolism (VTE) with the use of antipsychotics. An increasing number of observational studies indicate an elevated risk of VTE in antipsychotic drug users. Although the use of certain antipsychotics has been associated with VTE, current data can neither conclusively verify differences in occurrence rates of VTE between first- and second-generation antipsychotics or between individual compounds, nor identify which antipsychotic drugs have the lowest risk of VTE...
February 8, 2018: CNS Drugs
https://www.readbyqxmd.com/read/29409162/antipsychotic-reduction-and-or-cessation-and-antipsychotics-as-specific-treatments-for-tardive-dyskinesia
#17
REVIEW
Hanna Bergman, John Rathbone, Vivek Agarwal, Karla Soares-Weiser
BACKGROUND: Since the 1950s antipsychotic medication has been extensively used to treat people with chronic mental illnesses such as schizophrenia. These drugs, however, have also been associated with a wide range of adverse effects, including movement disorders such as tardive dyskinesia (TD) - a problem often seen as repetitive involuntary movements around the mouth and face. Various strategies have been examined to reduce a person's cumulative exposure to antipsychotics. These strategies include dose reduction, intermittent dosing strategies such as drug holidays, and antipsychotic cessation...
February 6, 2018: Cochrane Database of Systematic Reviews
https://www.readbyqxmd.com/read/29395607/a-quantitative-systems-pharmacology-study-on-optimal-scenarios-for-switching-to-paliperidone-palmitate-once-monthly
#18
Hugo Geerts, Athan Spiros, Patrick Roberts, Larry Alphs
Long-acting injectable (LAI) antipsychotic formulations are increasingly used for improving patient compliance and long-term outcomes. Transitioning to LAIs raises questions regarding how optimum efficacy can be rapidly achieved while minimizing potential efficacy and safety concerns related to overlapping plasma levels of prior treatments and the new LAI. Ideally, randomized clinical trials would provide guidance regarding transition algorithms, but the number of studies and sample size required to address relevant questions makes this approach unachievable...
January 25, 2018: Schizophrenia Research
https://www.readbyqxmd.com/read/29359582/paliperidone-palmitate-three-month-depot-formulation-a-helpful-innovation-with-practical-pitfalls
#19
Judith D Hope, Nicholas A Keks
OBJECTIVE: Paliperidone palmitate is now available as a three-month depot injection. This paper will review the pharmacokinetics, pharmacodynamics, efficacy and tolerability, as well as practical issues and pitfalls for clinicians with this innovative treatment for schizophrenia. CONCLUSION: The three-month depot formulation of paliperidone for the treatment of schizophrenia is not a new compound. The nanocrystalline structure of the three-month formulation is larger and takes longer to disperse than the one-month formulation, hence its extended depot action...
January 1, 2018: Australasian Psychiatry: Bulletin of Royal Australian and New Zealand College of Psychiatrists
https://www.readbyqxmd.com/read/29356004/training-switching-focus-with-a-mobile-application-by-a-patient-suffering-from-avh-a-case-report
#20
Lucia Visser, Igne Sinkeviciute, Iris E Sommer, Josef J Bless
Auditory verbal hallucinations complicate many psychiatric disorders. Antipsychotic medication is effective in the majority, but a significant minority experiences high burden from resistant hallucinations. Here, we aim to improve executive control, in an attempt to decrease burden from hallucinations. We describe the use of a cognitive trainings app by a young woman with highly resistant hallucinations. With modest training, a significant decrease in the duration of hallucinations was reached. Possibilities of this training technique are discussed...
February 2018: Scandinavian Journal of Psychology
keyword
keyword
88298
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"